Health Canada’s safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors — e.g., Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin) — concluded in July 2018 with the finding that there may be a link between the use of SGLT2 inhibitors and acute pancreatitis. However there was limited evidence to suggest a link with chronic pancreatitis. Health Canada is working with the manufacturers to update the Canadian product monographs, or drug labels, for SGLT2 inhibitors to include this increased risk of pancreatitis.